GenMont Biotech Inc
TWSE:3164

Watchlist Manager
GenMont Biotech Inc Logo
GenMont Biotech Inc
TWSE:3164
Watchlist
Price: 24.4 TWD -0.2% Market Closed
Updated: May 24, 2024

Profitability Summary

GenMont Biotech Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
GenMont Biotech Inc

Revenue
354.8m TWD
Cost of Revenue
-117.8m TWD
Gross Profit
237m TWD
Operating Expenses
-201.5m TWD
Operating Income
35.5m TWD
Other Expenses
24m TWD
Net Income
59.5m TWD

Margins Comparison
GenMont Biotech Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
TW
GenMont Biotech Inc
TWSE:3164
2.1B TWD
67%
10%
17%
US
Abbvie Inc
NYSE:ABBV
277.6B USD
66%
29%
11%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
66%
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.4B USD
87%
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.5B USD
86%
30%
29%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81.7B USD
76%
32%
2%
US
Moderna Inc
NASDAQ:MRNA
63.1B USD
22%
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
31.8B USD
75%
22%
12%
KR
Celltrion Inc
KRX:068270
37.3T KRW
47%
21%
17%
Country TW
Market Cap 2.1B TWD
Gross Margin
67%
Operating Margin
10%
Net Margin
17%
Country US
Market Cap 277.6B USD
Gross Margin
66%
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 163.2B USD
Gross Margin
66%
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 117.4B USD
Gross Margin
87%
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 108.5B USD
Gross Margin
86%
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81.7B USD
Gross Margin
76%
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 63.1B USD
Gross Margin
22%
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 31.8B USD
Gross Margin
75%
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 37.3T KRW
Gross Margin
47%
Operating Margin
21%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
GenMont Biotech Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
TW
GenMont Biotech Inc
TWSE:3164
2.1B TWD
5%
3%
2%
2%
US
Abbvie Inc
NYSE:ABBV
277.6B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.4B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108.5B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
135.7B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81.7B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
63.1B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
31.8B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
37.3T KRW
4%
3%
4%
3%
Country TW
Market Cap 2.1B TWD
ROE
5%
ROA
3%
ROCE
2%
ROIC
2%
Country US
Market Cap 277.6B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 163.2B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 117.4B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 108.5B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 135.7B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81.7B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 63.1B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 31.8B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 37.3T KRW
ROE
4%
ROA
3%
ROCE
4%
ROIC
3%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More